Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;21(1):e8-e17.
doi: 10.3747/co.21.1579.

Pheochromocytoma and paraganglioma syndromes: genetics and management update

Affiliations

Pheochromocytoma and paraganglioma syndromes: genetics and management update

M Lefebvre et al. Curr Oncol. 2014 Feb.

Abstract

Pheochromocytomas (pheos) and paragangliomas (pgls) are rare tumours of the autonomic nervous system, originating from paraganglia, which are dispersed neuroendocrine organs characterized by catecholamine and peptide-producing cells derived from the neural crest. Medical textbooks have traditionally suggested that 10% of pheos are heritable. However, the frequency of heritable pheo has been underestimated. Three syndromic conditions-Von Hippel-Lindau (vhl), multiple endocrine neoplasia type 2 (men2), and neurofibromatosis type 1 (nf1)-and three genes-subunits of the succinate dehydrogenase (SDH) complex: SDHB, SDHC, and SDHD-are established causes of hereditary pheo-pgl. In the last few years, four new genes (SDHA, SDHAF2, MAX, and TMEM127) have been found to be associated with predisposition to these tumours. The present review, illustrated by three case reports, gives an update of the genetic basis of pheo-pgl and of the parent-of-origin effect implicated in the transmission of SDHD and SDHAF2. We discuss the referral criteria that should guide the decision to offer genetic testing to affected patients. We also specify the genes that are most likely implicated-based on particular features such as malignancy, bilateralism, or childhood-onset-to help geneticists efficiently order appropriate genetic tests. Finally, we review the screening recommendations for carriers of a pheo-pgl predisposition mutation.

Keywords: Pheochromocytoma; genetics; management; paraganglioma; parent-of-origin effect; predisposition; screening; testing.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Pedigree of patient 3. Squares = men; circles = women; filled symbols = tumour-affected individuals (diagnoses indicated); diagonal line = deceased person; arrow = proband; number(y) = age or age at diagnosis in years; Dx = diagnosed at; R = right; L = left.
FIGURE 2
FIGURE 2
Transmission of the SDHD gene and the parent-of-origin effect. The inactivation of both SDHD genes can be explained by a germline mutation (transmitted by a parent—usually the father, but in rare instances, the mother) in one allele and by a somatic mutation or loss (present only in the tumour) of the other allele. Loss of the maternal 11p15 region is also a somatic event.
FIGURE 3
FIGURE 3
Referral and testing protocol (based on Fishbein and Nathanson, Jimerez et al., Gimenez–Roqueplo et al., Jafri and Maher, and Erlic et al.15). The numbering system in the boxes refers to the likelihood of identifying mutations, with 1 being most likely. Criteria in the middle should trigger a referral to oncogenetics. Pheo = pheochromocytoma; Pgl = paraganglioma; ihc = immunohistochemistry.

References

    1. Dumas N, Edmont M, Grunenwald S, et al. Characterisation of genetics aspects of paragangliomas and pheochromocytomas in the Quebec French-Canadian population. Presented at the 12th International Congress of Human Genetics; Montreal, QC. October 11–15, 2011; [Available online at: http://www.ichg2011.org/cgi-bin/showdetail.pl?absno=10669; cited June 17, 2013]
    1. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma–paraganglioma syndromes. J Intern Med. 2009;266:19–42. doi: 10.1111/j.1365-2796.2009.02111.x. - DOI - PMC - PubMed
    1. Kirmani S, Young WF. Hereditary paraganglioma–pheochromocytoma syndromes. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews. Seattle, WA: University of Washington; 1993. [Available online at: http://www.ncbi.nlm.nih.gov/books/NBK1548; cited August 30, 2012] - PubMed
    1. DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. WHO Classification of Tumours Pathology and Genetics Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
    1. Erlic Z, Neumann HPH. Familial pheochromocytoma. Hormones. 2009;8:29–38. doi: 10.14310/horm.2002.1219. - DOI - PubMed

LinkOut - more resources